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RIFT VALLEY FEVER VIRUS: A REVIEW OF RECENT DATA
LE VIRUS DE LA FIÈVRE DE LA VALLÉE DU RIFT :
UNE REVUE DES DONNÉES RÉCENTES
Par Michèle BOULOY(1)
(Communication présentée le 3 décembre 2009)
Le virus de la fièvre de la vallée du Rift (RVFV) est à l’origine de grandes épidémies, caractérisées par
un épisode fébrile, souvent mortel, chez les hommes et les animaux des régions sub-sahariennes et
de la Péninsule Arabique. Le RVFV appartient à la famille Bunyaviridae, et au genre Phlebovirus. Comme
tous les autres membres de cette vaste famille, ce virus est équipé d’un génome constitué d’un ARN
négatif segmenté (trois segments) avec une polarité négatif/ambisens, empaqueté dans une nucléo-
capside protéinique et finalement enveloppé dans une membrane à deux épaisseurs comportant deux
glycoprotéines virales. Au cours de ces dernières années, le RVFV a fait l’objet d’une attention accrue
en ce qui concerne son épidémiologie, sa biologie moléculaire, et ses mécanismes de virulence. Dans
notre revue, nous donnons un aperçu sur les caractéristiques essentielles de cet agent pathogène impor-
tant, et nous rendons compte des derniers développements dans ce domaine très actif de recherche.
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Rift Valley fever virus (RVFV) causes large outbreaks of acute febrile and often fatal illness among
humans and domesticated animals in sub-saharan Africa and the Arabian Peninsula. The RVFV is of
the genus Phlebovirus, within the family Bunyaviridae. Like all members of this large family, it con-
tains a three-segmented RNA genome of negative/ambisense polarity, packaged into viral nucleo-
capsid protein, and finally surrounded by a lipid bilayer containing two viral glycoproteins. RVFV epi-
demiology, molecular biology, and virulence mechanisms have raised considerable interest over the
past years. In the present article, we provide an overview of the basic features of this significant
pathogen, and of the latest developments in this highly active research field.
Key words: Bunyaviridae, genus Phlebovirus, pathogenesis, vaccines.
SUMMARY
10_bouloy:C2-Bastien  20/04/10  15:58  Page 377
COMMUNICATION
378 Bull. Acad. Vét. France — 2009 - Tome 162 - N°4/5 http://www.academie-veterinaire-defrance.org
INTRODUCTION
Viruses within the Bunyaviridae family are classified into five
genera:Orthobunyavirus,Nairovirus, Phlebovirus,Hantavirus and
Tospovirus (Nichol et al. 2005 ; Schmaljohn & Nichol, 2007 ;
Schmaljohn 2007). Tospoviruses infect plants while the other
bunyaviruses infect vertebrates. Several bunyaviruses including
Rift Valley fever virus (RVFV), La Crosse, Crimean-Congo
hemorrhagic fever, Hantaan and sin nombre viruses are res-
ponsible for potentially lethal hemorrhagic fevers and therefore
are of significant medical and public health importance.
Hantaviruses are transmitted by rodents whereas the other
bunyaviruses are transmitted by arthropods: mosquitoes (ortho-
bunyaviruses), phlebotomes (Phleboviruses), ticks
(Nairoviruses) and thrips (Tospoviruses).
Rift Valley fever virus (RVFV) belongs to the genus Phlebovirus,
family Bunyaviridae. It is a serious emerging pathogen affecting
humans and livestock. Since the first description of an outbreak
in Kenya 1931 (Daubney et al. 1931), recurrent epidemics have
killed hundreds of thousands of animals, more than a thousand
humans, and caused significant economic losses. During the last
decades, serious outbreaks occurred in Egypt, West Africa, East
and South Africa (Kenya, Tanzania and Somalia), Madagascar
and in 2000 the virus spread to the Arabian Peninsula provo-
king two simultaneous outbreaks in Yemen and Saudi Arabia
(Swanepoel & Coetzer, 2004). Recently, the virus was repor-
ted in the Comoros, including Mayotte. In East and South
Africa, epidemics and epizootics are associated with periods of
unusually heavy rains and the warm phase of El Nino. In spite
of intense circulation during outbreaks and its ability to infect
a wide range of hosts, the virus displays relatively low genetic
diversity.
RVFV is transmitted to animals by many mosquito species
(Aedes,Anopheles,Culex, Eretmapoites,Mansonia), but has also
been shown to be transmitted by other vectors, e.g. sand flies
or by contact with infected material. Infected animals develop
necrotic hepatitis, hemorrhage and abortion, with death rates
up to 100% among newborn animals. Lambs and kids are less
susceptible but develop acute disease associated with high
fever, weakness and anorexia. Some animals may exhibit
melaena, foetid diarrhoea, nasal discharge and icterus. In
adults animals RVFV infection is often asymptomatic, but the
virus manifests itself by high rates of abortions which may vary
from 15 to 100%.
Humans are often infected by close contact with sick animals
which may occur during herding, slaughtering and butchering,
milking or birthing livestock and through veterinary manipu-
lations. The disease in human is associated with symptoms ran-
ging from uncomplicated acute febrile illness to retinitis, hepa-
titis, renal failure, meningoencephalitis, severe hemorrhagic
disease, and death. Platelet dysfunction, thrombocytopenia and
depletion of coagulation factors are observed in many cases.
Elevated levels of serum aspartate and alanine aminotransfe-
rases are recorded even in the mild clinical forms. The hemor-
rhagic syndrome probably results from an increased endothe-
lium permeability due to capillary injuries, as for other viral
hemorrhagic fevers. Although the mortality rate for humans was
reported to be approximately 2%, in recent outbreaks it went
up to 35% (LaBeaud et al. 2008).
The severity of RVFV zoonosis, its capability to cause major epi-
demics among livestock and humans, and the lack of efficient
prophylactic and therapeutic measures make infection with this
pathogen a serious public health concern not only in endemic,
developing countries, but also in many non-endemic industrial
countries (Morrill & McClain, 1996). Authorities have the-
refore listed RVF as a notifiable disease and classified RVFV as
a BSL-3 or BSL-3+/4 agent respectively, in Europe and in the
US, and a potential biological weapon.
During the past years, there was an increased interest in RVFV
epidemiology, molecular biology, and virulence mechanisms.
Here, we will try to provide an overview over the basic features
of this significant pathogen, and review the latest developments
in this highly active research field.
VIRION STRUCTURE
Early ultrastructural studies by electron microscopy and nega-
tive staining (Ellis et al. 1979) described RVFV particles mea-
suring 90-110 nm in diameter. The envelope is composed of a
lipid bilayer containing the Gn and Gc glycoproteins forming
surface subunits, 5-8 nm in length, regularly arranged on its sur-
face. The viral ribonucleoproteins (RNPs) composed of the
three genomic segments associated with numerous copies of the
nucleoprotein N and the RNA dependent RNA polymerase L
are packaged into the virion. More recent studies by cryo-elec-
tron microscopy (Freiberg et al. 2008; Huiskonen et al. 2009;
Sherman et al. 2009) have changed the former view that
phleboviruses are pleiomorphic. Instead, these studies indica-
ted that the virion is likely to have an icosahedral symmetry:
the structure of RVFV is surprisingly ordered and the surface
covered by a shell of 122 glycoprotein capsomers arranged in
an icosahedral lattice with T=12.
THE VIRAL GENOME
Bunyaviruses are enveloped and have a tri-segmented single-stran-
dedRNAgenome of negative or ambisense polarity (Elliott 1996).
The genome segments of bunyaviruses encode four structural pro-
teins: the viral polymerase (L) on the large (L) segment, two gly-
coproteins (Gn and Gc) on the medium (M) segment, and the
viral nucleocapsid protein (N) on the smallest (S) segment. RVFV
additionally expresses two nonstructural proteins encoded on the
M segment, a 78kDa protein and a 14kDa protein also called
NSm1 and NSm2 (Gerrard &Nichol, 2007), and one on the S
segment, termed NSs. These nonstructural proteins are dispen-
sable for viral multiplication in cell culture, but play important
roles for pathogenesis in vivo (Vialat et al. 2000;Won et al. 2006;
Bird et al. 2007 ; Gerrard et al. 2007).
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The three genomic RNA segments of bunyaviruses contain
untranslated regions (UTRs) at the 3’ and 5’ ends which are
segment-specific and serve as promoters for transcription and
replication by the viral polymerase. The terminal sequences of
the UTRs are conserved and form panhandle structures which
give the RNPs a circular appearance when observed by elec-
tron microscopy for review, (Elliott 1996). For RVFV, the L and
M segments are of negative polarity while the S segment uti-
lizes an ambisense strategy to code for both N and NSs (Giorgi
et al. 1991). The coding capacity of the genome is depicted in
figure 1A. The general view that only the viral, negative-sense
genome is incorporated into the mature particle must be revi-
sed as a small but significant fraction of the antigenomes i.e.
replicative intermediates have been detected in purified RVFV
particles (Ikegami et al. 2005).
VIRAL REPLICATION CYCLE AND THE ROLE
OF VIRAL GENE PRODUCTS
Transcription and replication
The general features of RVFV transcription and replication are
similar to those of other negative stranded RNA viruses (Elliott
1996; Schmaljohn & Nichol, 2007). Transcription and repli-
cation take place in the cytoplasm. During the replication cycle,
each segment is transcribed into a mRNA and is replicated
through a process which involves the synthesis of the exact copy
of the genome, called complementary RNA (cRNA) or anti-
genome. For Phleboviruses, and RVFV in particular, the cRNA
representing the copy of the S ambisense segment serves as tem-
plate for the synthesis of the NSs mRNA. Since some cRNA
is also present in the input virus, the virulence factor NSs is
expressed immediately after the virus has entered the host cell.
Bunyaviral mRNA synthesis in general is initiated through a
cap-snatching mechanism by which host mRNAs are cleaved
through an endonuclease activity of the L protein to obtain 10
to 18 nucleotide-long primers for transcription. Synthesis of
cRNA and vRNA does not require an oligonucleotide primer
and is directly initiated with 5’ nucleoside triphosphates.
cRNA represents a complete copy of the vRNA, whereas
mRNAs terminate before the 5’ end of the template. The
mechanism of the switch between transcription and replication
remains unknown. Moreover, although RNA-dependent poly-
merase consensus motifs are present in the RVFV L protein
(Muller et al. 1994), the domains responsible for the different
activities have not been defined precisely.
Minigenome systems have been helpful to analyze some steps
in RNA synthesis, i.e. transcription, replication, transcription
termination, and packaging. Minigenomes are similar to viral
genome segments but the viral ORF is replaced by a reporter
gene. Minigenomes are usually expressed either fromT7- or from
Pol I-based promoter plasmids, or transcribed in vitro and
transfected as RNA. Early on, studies with minigenomes have
established that transcription and replication requires the N and
L proteins (Lopez et al. 1995) confirming that naked vRNA
cannot be transcribed. Analysis of the RVFVRNPs showed that
the N protein is able to establish intermolecular interactions
through several amino-acids located in the N terminal region
of the protein which are conserved among phlebovirus N
sequences (Le May et al. 2005). The ability of N to form oli-
gomers may be a conserved feature in bunyaviruses. The L pro-
tein, probably in association with N, is able to perform both
transcription and replication, excluding the possibility that the
L protein is modified by a third viral factor to function as a repli-
case.
When compared to each other, the L, M and S segment-based
minigenomes do not express identical levels of reporter gene.
This indicates differential promoter activities associated with
the UTRs (Gauliard et al. 2006). Although the mutagenesis ana-
lysis was not as extensive as the one carried out for Uukuniemi
virus (Flick et al. 2002), it appeared that some of the conser-
ved UTR nucleotides play an important role in promoter acti-
vity and the regulation of gene expression (Prehaud et al. 1997).
RVFVmRNAs are not polyadenylated at their 3’end. They have
a shortened 3’ end relative to the full-length cRNA, suggesting
that a specific termination signal is recognized during trans-
cription. Preliminary data had indicated that a conserved
motif is present in the intergenic region of the S segment of the
phleboviruses Toscana (TOSV), Sandfly fever Sicilian (SFSV),
and RVFV (Giorgi et al. 1991; Gro et al. 1992). Albarino et al.
mapped precisely the 3’ ends of the L, M, N and NSs mRNAs
of TOSV, SFSV and RVFV, and identified a sequence motif 3’-
C1-3GUCG/A-5’ which is conserved on the M and S segments
of phleboviruses (Albarino et al. 2007). With regard to the L
segment mRNA, conflicting data were reported, showing
either that it is a full-length 3’ end (Albarino et al. 2007) or that
a short sequence at the 3’ end is missing (Ikegami et al. 2007).
Glycoproteins and particle formation
The RVFV envelope glycoproteins mediate particle entry into
cells through receptors which, remain to be identified. RVFV
entry is predicted to employ a class II fusion mechanism that
is activated by low pH following endocytosis of the virion
(Filone et al. 2006). The RVFVM segment encodes Gn (enco-
ded by amino-terminal sequences) andGc (encoded by carboxy-
terminal sequences) as well as two nonstructural proteins
NSm1 (78kDa) and NSm2 (14kDa). The NSm1 and NSm2
proteins are produced by alternative use of the first and second
of the 5 in-frame AUG codons, respectively, which are present
at the 5’ end of the M mRNA, i.e. upstream of the Gn
sequence (figure 1B). The role of these proteins will be discus-
sed further below.
Like all bunyaviruses, RVFV particles usually bud into the lumen
of the Golgi apparatus (Elliott 1996). Both RVFV Gn and Gc
localize to the Golgi apparatus when expressed together from
polyprotein-expressing plasmids (Wasmoen et al. 1988)When
expressed alone, Gn is transported to the Golgi apparatus due
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to a specific Golgi localization motif, whereas Gc localized to
the endoplasmic reticulum (ER) due to the presence of a spe-
cific ER retention signal (Gerrard & Nichol, 2002). This sug-
gests that Gc moves to the Golgi apparatus via its physical asso-
ciation with Gn.
The minigenome systems expressing a reporter gene were also
useful to investigate viral packaging activity. In that case, the
glycoproteins were co-expressed with the transcription machi-
nery to allow formation of viral like particles (VLPs) released
into the medium (Habjan et al. 2009a).When observed by elec-
tron microscopy and negative staining, these particles resem-
bled RVFV particles in size and morphology. They were able to
infect naïve cells and to undergo the first step of the replica-
tion cycle, i. e. primary transcription. If both L and N were pro-
vided in trans, replication of minigenomes also occurred.
Reverse genetics
Reverse genetics systems allow to freely manipulate the viral
genome and to dissect individual steps in the viral multiplica-
tion cycle. Fully infectious, recombinant virus particles can be
recovered from cloned cDNA plasmids if the minireplicon is
replaced by constructs for the full-length viral RNA segments.
This technique was first established for Bunyamwera virus, the
prototype of the Bunyaviridae (Bridgen & Elliott, 1996). These
rescue systems were based on T7-transgenic cells to express the
constructs for the viral genome segments and the helper pro-
teins N and L (Ikegami et al. 2006 ; Gerrard et al. 2007), but
promoters for the cellular pol I could also be used to express the
genome segments (Billecocq et al. 2008; Habjan et al. 2008b).
The cell lines (BSR-T7 or BHK-T7) used for T7 expression are
deficient in the RIG-I pathway (Habjan et al. 2008a) which
would normally respond to the 5’ triphosphorylated T7 trans-
cripts with the production of the antiviral IFNs.
Depending on the laboratory which developed the rescue
system, the genetic backbone of the recombinant virus was based
either on the attenuated strain MP12 (Ikegami et al. 2006 ;
Billecocq et al. 2008), or the virulent strains ZH501 (Gerrard
et al. 2007) or ZH548 (Billecocq et al. 2008; Habjan et al.
2008b).
ROLE OF THE NON-STRUCTURAL PROTEINS
The establishment of reverse genetics systems has opened the
door for studies of RVFV molecular biology and pathogenesis
which were unthinkable a few years ago.
The role of NSs in virulence
NSs of RVFV forms a ribbon-like filament in the nucleus
(Struthers & Swanepoel, 1982; Swanepoel & Blackburn,
1977) (figure 2). This feature is unexpected for a virus replicating
in the cytoplasm. Moreover, it is particular to RVFV and not
shared with NSs proteins of other bunyaviruses. NSs was cha-
racterized as a major virulence factor counteracting the anti-
viral IFN system (Vialat et al. 2000 ; Bouloy et al. 2001;
Billecocq et al. 2004). It has become clear meanwhile that NSs
is a multifunctional protein inhibiting cellular basic transcription
and suppressing two different arms of the IFN response, namely
(i) IFN induction by a specific, early, mechanism
(ii) the antiviral protein PKR.
With respect to specific suppression of IFN induction, the cel-
lular protein SAP30 was identified as interacting with NSs.
SAP30 belongs to the Sin3A/NCoR/HDAC repressor com-
Figure 1:Genome and expres-
sion strategies of RVFV.
(A) Schematic representation of
the three genomic segments L
(large), M (medium) and S
(small) and the proteins encoded
on them.
(B)The mRNA transcribed from
the M segment contains five in-
frame start codons which gove rise
to the 78kDa and the 14 kDa
proteins, as well as some minor
products (Gerrard & Nichol,
2007). Scissors indicate host cell
protease sites for cleavage of the
polyproteins.
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plexes intervening in gene transcription regulation (Le May et
al. 2008). Moreover, SAP30 interacts directly with YY1, a trans-
cription factor involved in the regulation of expression of nume-
rous genes, including IFN-. Through a series of co-immuno-
precipitation, confocal microscopy and chromatin
immunoprecipitations, it was demonstrated that NSs, SAP30,
YY1 and Sin3A-associated corepressors are recruited on the IFN-
 promoter inhibiting CBP recruitment, histone acetylation and
transcriptional activation. Using reverse genetics, a recombi-
nant ZH548 in which NSs was deleted of the SAP30 interac-
tion domain was produced. Still located in the nucleus, this
mutant protein was not able to form filaments. In contrast with
the wt virus, this mutant, ZH548-NSs210-230, induced
IFN- expression and was unable to kill mice. Further analyses
on the wt NSs filament indicated that, even though cellular
DNA is mostly excluded from the filament, heterochromatin
clusters of pericentromeric gamma satellite sequences appea-
red intimately associated with NSs (Mansuroglu et al. 2009).
This results in a high incidence of nuclear anomalies, transla-
ting chromosome cohesion and segregation defects which
could contribute to RVFV pathology.
NSs also suppresses cellular gene expression by a more general
mechanism which relies on the interaction with the host cell
protein p44. p44 is a subunit of the TFIIH basal transcription
factor and becomes sequestered into the NSs filamentous struc-
ture characteristic of RVFV infection (Le May et al. 2004). As
a consequence, TFIIH cannot assemble and its concentration
drops rapidly, explaining the drastically reduced transcriptional
activity of cells infected with RVFV. Interestingly, NSs functions
as a general inhibitor of Pol II as well as Pol I, since TFIIH is
involved in transcription by both these host polymerases.
Inhibition of TFIIH and hence general transcription is a rela-
tively late event occurring after 8 h of infection, whereas the spe-
cific inhibition of IFN- transcription (mediated by SAP30
recruitment) is in place as early as 3-4 h after infection.
Very recently, a novel function of NSs was described, the tar-
geting of the antiviral, IFN-induced protein kinase PKR
(Habjan et al. 2009b; Ikegami et al. 2009). PKR is a serine-threo-
nine kinase activated by viral RNAs and mediating a stop of
translation. NSs-dependent degradation is specific for PKR and
occurs through the proteasome. Hence, cells infected with
RVFV are devoid of PKR, whereas PKR was clearly detected
and activated by infection with NSs-deleted virus strains, e.g.
Clone 13. Interestingly, it was also observed that this activity
is specific to RVFVNSs and not shared with other Phleboviruses
like Sandfly fever Sicilian virus or the orthobunyavirus LaCrosse.
Altogether, it appears that NSs has multiple functions to
counteract the IFN system, either at the transcriptional level
or at the translational level by degrading PKR.
The role of the NSm protein as a virulence
factor and a suppressor of virus-induced
apoptosis
The biological function of the NSm1 and NSm2 proteins was
addressed by producing RVFV mutants with either a deletion
in the pre-Gn region or point mutations in the start codons of
the two respective reading frames (Gerrard et al. 2007; Won et
al., 2006). In all cases, virus growth in cell culture was similar
to the parental viruses. However, when the pre-Gn deletion was
introduced into the MP12 strain, plaques were larger than for
the parental MP12 strain and a more extensive apoptosis due
to elevated caspase activity was observed (Won et al., 2007).
NEW INSIGHTS FOR THE DEVELOPMENT
OF VACCINES
The only vaccine commercially available, was developed by
Smithburn (Smithburn 1949) who passaged the Entebbe iso-
late in mice and eggs to attenuate the virulence However, the
passaged virus, called the Smithburn strain, had lost only par-
tially its virulence: it induces abortions and teratogenesis in ewes,
so that its use is restricted to periods of intense RVFV circula-
tion and pregnant animals cannot be vaccinated.
A more recent attenuated virus MP12 obtained after 12 pas-
sages in the presence of a mutagen was immunogenic but is still
found abortigenic during a vaccination trial in ewes (Hunter
et al. 2002). An alternative candidate is the natural virus, Clone
13, which lacks more than 70% of the coding sequence for the
IFN antagonist NSs and is avirulent for mice, sheep and cattle,
but highly immunogenic (Muller et al. 1995).
Figure 2: RVFV NSs forms a
filamentous structure in the
nucleus
Confocal microscopy picture sho-
wing a section of a L929 cell
nucleus infected by ZH548 and
stained with the DNA intercala-
ting dye ToPro3 (red), with anti-
NSs antibodies (green) and
merge. The cellular DNA is pre-
dominantly excluded from the
filament. (From Mansuroglu et
al. 2009)
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While the deletion in Clone 13 was obtained naturally, it is now
possible to manipulate the viral genome via reverse genetics,
opening ways to abrogate its pathogenicity. The NSs and
NSm sequences are obvious targets to produce live attenuated
RVFV. Several attenuated recombinant RVFV were created:
rMP12 in which the NSs sequence was deleted partially as in
Clone 13 or completely (Ikegami et al. 2006) and rZH548NSs
(Billecocq et al. 2008; Habjan et al. 2008b), rZH501NSs or
rZH501NSs/NSm (Bird et al., 2007 ; Bird et al., 2008 ) cha-
racterized by the complete deletion of NSs and/or NSm pro-
duced in the ZH548 or ZH501 genetic context, respectively.
RVFV mutant lacking NSm are somewhat attenuated compa-
red to wt RVFV but can still cause either acute lethal hepatic
necrosis or delayed lethal neurologic disease (Bird et al. 2007).
The double deletion mutants induced robust anti-RVF virus
antibody responses and 100% protection from a lethal challenge
(Bird et al. 2008).
Sub-unit recombinant vaccine candidates expressing the RVFV
glycoproteins have been described for reviews (Bouloy &
Flick, 2009; Ikegami &Makino, 2009): they used different vec-
tors such as the lumpy skin disease vector or the alphavirus or
adenovirus vectors. Other groups have developed another
type of sub-unit vaccine by expressing the RVFV glycoproteins
which can assemble into VLPs. For efficient production,
recombinant baculovirus were constructed expressing the gly-
coproteins alone or in association with N (Liu et al. 2008).
DNA-based vaccine administrated by gene gun has also been
described but required several immunizations.
Thus, the recently gained knowledge on RVFV molecular
biology already proved useful for the understanding and deve-
lopment of modern vaccine candidates (Bouloy & Flick, 2009;
Ikegami&Makino, 2009), and future findings will certainly help
to develop antivirals and strategies to combat this important
pathogen.
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